Epidemiology and regional variation of nonsusceptible and multidrug-resistant Pseudomonas aeruginosa isolates from intensive versus non-intensive care units across multiple centers in the United States

被引:5
|
作者
Puzniak, Laura [1 ]
DePestel, Daryl D. [1 ]
Yu, Kalvin [2 ]
Ye, Gang [2 ]
Gupta, Vikas [2 ]
机构
[1] Merck & Co Inc, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA
[2] Becton Dickinson & Co, 1 Becton Dr, Franklin Lakes, NJ 07417 USA
关键词
Antibacterial resistance; ICU; Multidrug resistance; Nonsusceptible; Pseudomonas aeruginosa; VENTILATOR-ASSOCIATED PNEUMONIA; INICC REPORT; INFECTION; SUSCEPTIBILITY; COUNTRIES; SURVEILLANCE; PREVALENCE; ORGANISMS; OUTCOMES; RISK;
D O I
10.1016/j.diagmicrobio.2020.115172
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Nonsusceptible (NS) and multidrug-resistant (MDR) Pseudomonas aeruginosa (PsA) infections are associated with considerable mortality. This retrospective study assessed NS PsA and MDR PsA prevalence in US intensive care unit (ICU) and non-ICU settings. We evaluated nonduplicate PsA isolates collected in 2017. Data were classified by hospital admission setting. PsA isolates were evaluated for NS to each of 4 drug classes and MDR. Significantly higher rates of NS PsA and MDR PsA were found in ICU versus non-ICU settings (P < .001), except for respiratory isolates, which had high rates regardless of setting; rates also correlated with source, hospital size, urban/rural status, and geographic region. NS PsA isolates for each antibacterial category (except fluoroquinolones) and MDR PsA were significantly more likely to be classified as hospital-onset than admission-onset (P < .001). These data are consistent with previous reports and emphasize the importance of testing for resistant infection upon admission and when treating hospital-acquired infections. (C) 2020 Published by Elsevier Inc.
引用
收藏
页数:7
相关论文
共 16 条
  • [1] Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents
    Asempa, Tomefa E.
    Nicolau, David P.
    Kuti, Joseph L.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2019, 57 (08)
  • [2] Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units:: Role of antibiotics with antipseudomonal activity
    Paramythiotou, E
    Lucet, JC
    Timsit, JF
    Vanjak, D
    Paugam-Burtz, C
    Trouillet, JL
    Belloc, S
    Kassis, N
    Karabinis, A
    Andremont, A
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (05) : 670 - 677
  • [3] In Vitro Activities of Various Antimicrobials Against Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Strains Isolated from Intensive Care Units
    Senol, Arzu
    Celik, Ilhami
    [J]. FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, 2021, 26 (01): : 96 - 103
  • [4] Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012
    Hackel, Meredith A.
    Badal, Robert E.
    Bouchillon, Samuel K.
    Biedenbach, Douglas J.
    Hoban, Daryl J.
    [J]. SURGICAL INFECTIONS, 2015, 16 (03) : 298 - 304
  • [5] In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units
    Timurkaynak, F
    Can, F
    Azap, ÖK
    Demirbilek, M
    Arslan, H
    Karaman, SÖ
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 27 (03) : 224 - 228
  • [6] The potential activity of biosynthesized silver nanoparticles of Pseudomonas aeruginosa as an antibacterial agent against multidrug-resistant isolates from intensive care unit and anticancer agent
    A. B. Abeer Mohammed
    Mona Mohamed Abd Elhamid
    Magdy Kamal Mohammed Khalil
    Abdallah Soubhy Ali
    Rateb Nabil Abbas
    [J]. Environmental Sciences Europe, 2022, 34
  • [7] The potential activity of biosynthesized silver nanoparticles of Pseudomonas aeruginosa as an antibacterial agent against multidrug-resistant isolates from intensive care unit and anticancer agent
    Mohammed, A. B. Abeer
    Abd Elhamid, Mona Mohamed
    Khalil, Magdy Kamal Mohammed
    Ali, Abdallah Soubhy
    Abbas, Rateb Nabil
    [J]. ENVIRONMENTAL SCIENCES EUROPE, 2022, 34 (01)
  • [8] Prevalence of multidrug-resistant, extensively drug-resistant, and pandrug-resistant Pseudomonas aeruginosa from a tertiary level Intensive Care Unit
    Gill, J. S.
    Arora, Sunil
    Khanna, S. P.
    Kumar, K. V. S. Hari
    [J]. JOURNAL OF GLOBAL INFECTIOUS DISEASES, 2016, 8 (04) : 155 - 159
  • [9] Molecular Epidemiology of Multidrug-Resistant Pseudomonas aeruginosa Acquired in a Spanish Intensive Care Unit: Using Diverse Typing Methods to Identify Clonal Types
    Adelantado Lacasa, Marta
    Eugenia Portillo, Maria
    Lobo Palanco, Joaquin
    Chamorro, Judith
    Ezpeleta Baquedano, Carmen
    [J]. MICROORGANISMS, 2022, 10 (09)
  • [10] Outcomes from ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas: results from 28 intensive care units
    C Parker
    J Kutsiogiannis
    J Muscedere
    D Cook
    P Dodek
    A Day
    D Heyland
    [J]. Critical Care, 11 (Suppl 2):